The press conference for the adjustment of the national medical insurance pharmaceutical catalog for 2024 was held today in Beijing. A reporter from the Star Daily learned on site that in this year's adjustment, 91 types of pharmaceuticals were newly added to the national medical insurance pharmaceutical catalog, with 89 types included through negotiation/bidding, and another 2 types of pharmaceuticals selected through national centralized procurement directly included. At the same time, 43 types of pharmaceuticals that have been clinically replaced or have not been produced or supplied for a long time were removed from the list. Among the 117 types of pharmaceuticals outside the list participating in negotiation/bidding this year, 89 types were successfully negotiated or bid, with the success rate and price reduction comparable to previous years. After this round of adjustments, the total number of pharmaceuticals in the national medical insurance catalog reached 3,159, including 1,765 western drugs and 1,394 Chinese patent medicines. The part of traditional Chinese medicine pieces consists of 892 types. It is understood that since its establishment, the National Medical Insurance Administration has continuously conducted drug catalog adjustment work for 7 years, adding a total of 835 types of pharmaceuticals to the national medical insurance pharmaceutical catalog, including 530 newly negotiated and 38 newly bid. At the same time, 438 types of pharmaceuticals with uncertain efficacy or prone to abuse, clinically eliminated, not produced or supplied for a long time, and replaceable by other varieties have been removed from the catalog.